参考文献/References:
[1] GOETZ L H,SCHORK N J.Personalized medicine:motivation,challenges,and progress[J].Fert Ster,2018,109(6):952-963.
[2] CARRASCO-RAMIRO F,PEIR-PASTOR R,AGUADO B.Human genomics projects and precision medicine[J].Gene Ther,2017,24(9):551-561.
[3] VAYENA E,BLASIMME A.Biomedical big data:new models of control over access,use and governance[J].J Bioethical Inquiry,2017,14(4):501-513.
[4] HUGHE S,DYFRIG A.Economics of pharmacogenetic-guided treatments:underwhelming or overstated?[J].Clin Pharmacol Therap,2018,103(5):749-751.
[5] YANG L,CUI H,YIN X,DOU H,ZHAO L,CHEN N,et al.Dependable and efficient clinical molecular diagnosis of Chinese RP patient with targeted exon sequencing[J].PLoS One,2015,10(10):e0140684.
[6] BIRTEL J,GLIEM M,MANGOLD E,MLLER P L,HOLZ F G,NEUHAUS C,et al.Next-generation sequencing identifies unexpected genotype-phenotype correlations in patients with retinitis pigmentosa[J].PLoS One,2018,13(12):e207958.
[7] PARMEGGIANI F,BARBARO V,MIGLIORATI A,RAFFA P,NESPECA P,DE NADAI K,et al.Novel variants of RPGR in X-linked retinitis pigmentosa families and genotype-phenotype correlation[J].Eur J Ophthalmol,2017,27(2):240-248.
[8] WHEWAY G,DOUGLAS A,BARALLE D,GUILLOT E.Mutation spectrum of PRPF31,genotype-phenotype correlation in retinitis pigmentosa,and opportunities for therapy[J].Exp Eye Res,2020,192:107950.
[9] HANNA E,RMUZAT C,AUQUIER P,TOUMI M.Gene therapies development:slow progress and promising prospect[J].J Mark Access Health Policy,2017,5(1):1265293.
[10] PETRS-SILVA H,LINDEN R.Advances in gene therapy technologies to treat retinitis pigmentosa[J].Clin Ophthalmol,2014,8:127-136.
[11] MOORE N A,MORRAL N,CIULLA T A,BRACHA P.Gene therapy for inherited retinal and optic nerve degenerations[J].Expert Opin Biol Ther,2018,18(1):37-49.
[12] DARROW J J.LUXTURNA:FDA documents reveal the value of a costly gene therapy[J].Drug Discov Today,2019,24(4):949-954.
[13] GHAZI N G,ABBOUD E B,NOWILATY S R,ALKURAYA H,ALHOMMADI A,CAI H,et al.Treatment of retinitis pigmentosa due to MERTK mutations by ocular subretinal injection of adeno-associated virus gene vector:results of a phase I trial[J].Human Genetics,2016,135(3):327-343.
[14] SLIJKERMAN R W,VACH C,DONA M,GARCA-GARCA G,CLAUSTRES M,HETTERSCHIJT L,et al.Antisense oligonucleotide-based splice correction for ush2a-associated retinal degeneration caused by a frequent deep-intronic mutation[J].Mol Ther Nucleic Acids,2016,5(10):e381.
[15] SANGERMANO R,GARANTO A,KHAN M,RUNHART E H,BAUWENS M,BAX N M,et al.Deep-intronic ABCA4 variants explain missing heritability in Stargardt disease and allow correction of splice defects by antisense oligonucleotides[J].Genet Med,2019,21(8):1751-1760.
[16] YAU E H,BUTLER M C,SULLIVAN J M.A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets[J].Exp Eye Res,2016,151:236-255.
[17] ZHU J,MING C,FU X,DUAN Y,HOANG D A,RUTGARD J,et al,Gene and mutation independent therapy via CRISPR-Cas9 mediated cellular reprogramming in rod photoreceptors[J].Cell Res,2017,27(6):830-833.
[18] 吴世靖.CRISPR/Cas9技术在遗传性眼病基因治疗中的应用[J].中华实验眼科杂志,2018,36(11):892.
WU S J.Applications of CRISPR/Cas9 genome editing technology in gene therapy for hereditary eye diseases[J].Chin J Exp Ophthalmol,2018,36(11):892.
[19] BAKONDI B,LV W,LU B,JONES MK,TSAI Y,KIM K J,et al.In vivo CRISPR/Cas9 gene editing corrects retinal dystrophy in the S334ter-3 rat model of autosomal dominant retinitis pigmentosa[J].Mol Ther,2016,24(3):556-563.
[20] LATELLA M C,DI SALVO M T,COCCHIARELLA F,BENATI D,GRISENDI G,COMITATO A,et al.In vivo editing of the human mutant rhodopsin gene by electroporation of plasmid-based CRISPR/Cas9 in the mouse retina[J].Mol Ther Nucleic Acids,2016,22,5(11):e389.
[21] SUZUKI K,TSUNEKAWA Y,HERNANDEZ-BENITEZ R,WU J,ZHU J,KIM E J,et al.In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration[J].Nature,2016,540(7631):144-149.
[22] PAN Z H,LU Q,BI A,DIZHOOR A M,ABRAMS G W.Optogenetic approaches to restoring vision[J].Ann Rev Vis Sci,2015,1(1):185-210.
[23] BI A,CUI J,MA Y P,OLSHEVSKAYA E,PU M,DIZHOOR A M,et al.Ectopic expression of a microbial-type rhodopsin restores visual responses in mice with photoreceptor degeneration[J].Neuron,2006,50(1):23-33.
[24] CRONIN T,VANDENBERGHE L H,HANTZ P,JUTTNER J,REIMANN A,KACS A E,et al.Efficient transduction and optogenetic stimulation of retinal bipolar cells by a synthetic adeno-associated virus capsid and promoter[J].EMBO Mol Med,2014,6(9):1175-1190.
[25] DOROUDCHI M M,GREENBERG K P,LIU J,SILKA K A,BOYDEN E S,LOCKRIDGE J A,et al.Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness[J].Mol Ther,2011,19(7):1220-1229.
[26] IVANOVA E,PAN Z H.Evaluation of the adeno-associated virus mediated long-term expression of channelrhodopsin-2 in the mouse retina[J].Mol Vis,2009,15:1680-1689.
[27] SUGANO E,ISAGO H,WANG Z,MURAYAMA N,TAMAI M,TOMITA H.Immune responses to adeno-associated virus type 2 encoding channelrhodopsin-2 in a genetically blind rat model for gene therapy[J].Gene Ther,2011,18(3):266-274.
[28] DOROUDCHI M M,GREENBERG K P,LIU J,SILKA K A,BOYDEN E S,LOCKRIDGE J A,et al.Virally delivered channelrhodopsin-2 safely and effectively restores visual function in multiple mouse models of blindness[J].Mol Ther,2011,19(7):1220-1229.
[29] BAKALL B,HARIPRASAD S M,KLEIN K A .Emerging gene therapy treatments for inherited retinal diseases[J].Ophthalmic Surg Lasers Imaging Retina,2018,49(7):472-478.
[30] MARTINEZ-FERNANDEZ DE LA CAMARA C,CEHAJIC-KAPETANOVIC J,MACLAREN R E.RPGR gene therapy presents challenges in cloning the coding sequence[J].Exp Opin Biol Ther,2020,20(1):63-71.
[31] 李淑贤,刘铁城,陈晓菲,代艾艾,高旭辉,李润璞.视网膜色素变性的基因治疗进展[J].解放军医学院学报,2017,38(1):82-84,88.
LI S X,LIU T C,CHEN X F,DAI A A,GAO X H,LI R P.Advances in gene therapy for retinitis pigmentosa[J].Acad J Chin PLA Med Sch Jan,2017,38(1):82-84,88.
[32] GREGOREVIC P,BLANKINSHIP M J,ALLEN J M,CRAWFORD R W,MEUSE L,MILLER D G,et al.Systemic delivery of genes to striated muscles using adeno-associated viral vectors[J].Nat Med,2004,10(8):828-834.
[33] AURICCHIO A,SMITH A J,ALI R R.The future looks brighter after 25 years of retinal gene therapy[J].Hum Gene Ther,2017,28(11):982-987.